University of Nottingham Industry – Academia Partnership Scheme 2016 for accelerating clinical translation of biomedical research (UNI-APS 2016)
Lead Research Organisation:
University of Nottingham
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The MRC Proximity to Discovery scheme awards universities funds to help develop new collaborations, and ways of exchanging knowledge and skills. The awards can be used to support activities that promote the value of academic-industry partnership, and enhance academic and industry researchers’ understanding of each other’s needs and capabilities. This may be through people exchanges, creation of technology demonstrators, showcase events, commercialisation workshops and ‘entrepreneurs in residence’ schemes. Such exchanges of knowledge and skills will boost the most fruitful collaborations between UK universities and life science companies.
Organisations
- University of Nottingham (Lead Research Organisation)
- AstraZeneca (United Kingdom) (Collaboration)
- CliniMed Ltd (Collaboration)
- Belfry Therapeutics (Collaboration)
- Axis Bio Services Ltd (Collaboration)
- GlaxoSmithKline (GSK) (Collaboration)
- BiBerChem Research Ltd (Collaboration)
- Sygnature Discovery Ltd (Collaboration)
People |
ORCID iD |
Publications
Lee JB
(2018)
Lipophilic activated ester prodrug approach for drug delivery to the intestinal lymphatic system.
in Journal of controlled release : official journal of the Controlled Release Society
Oglic D
(2018)
Active Search for Computer-aided Drug Design.
in Molecular informatics
Qin C
(2021)
Targeted delivery of lopinavir to HIV reservoirs in the mesenteric lymphatic system by lipophilic ester prodrug approach.
in Journal of controlled release : official journal of the Controlled Release Society
| Description | Catheter Against Urinary Tract Infection Trial: a randomised trial of antimicrobial-impregnated urinary catheters for long-term indwelling urinary catheter users (CAUTI Trial) |
| Amount | £2,077,821 (GBP) |
| Funding ID | NIHR127982 |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 05/2020 |
| End | 12/2023 |
| Description | Developing CDK12 inhibitors to treat Myotonic Dystrophy |
| Amount | £2,481,155 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 05/2022 |
| End | 01/2025 |
| Description | National Biofilms Innovation Centre PoC grant to Miguel Camara |
| Amount | £43,000 (GBP) |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | UoN MRC CiC Round 8: Pre-clinical development of a novel imidazole analogue for treatment of temozolomide-resistant tumours |
| Amount | £86,811 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2019 |
| End | 02/2020 |
| Description | Bayston: Urinary catheters |
| Organisation | CliniMed Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | A novel urinary catheter technology/device has been developed at UoN. This formed the basis of the project. |
| Collaborator Contribution | The partner provided regulatory and manufacturing support. |
| Impact | A successful NIHR EME grant has been awarded to commercialise this technology in partnership |
| Start Year | 2018 |
| Description | Bradshaw: Blood brain barrier |
| Organisation | Axis Bio Services Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | A candidate drug developed at UoN was contributed along with its synthetic route |
| Collaborator Contribution | In vitro and in vitro screening tools were contributed by the partners |
| Impact | A successful confidence in concept bid to take this concept further |
| Start Year | 2018 |
| Description | Bradshaw: Blood brain barrier |
| Organisation | Sygnature Discovery Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | A candidate drug developed at UoN was contributed along with its synthetic route |
| Collaborator Contribution | In vitro and in vitro screening tools were contributed by the partners |
| Impact | A successful confidence in concept bid to take this concept further |
| Start Year | 2018 |
| Description | Developing a new strategy to bypass permeability barriers in pseudomonas |
| Organisation | Belfry Therapeutics |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | The University of Nottingham (UoN) provided novel hit candidates that were to be further developed in partnership. |
| Collaborator Contribution | The PDRA learned new skills and insight in manipulating the chemistries that were introduced by UoN. |
| Impact | This project has facilitated and industrial collaboration with Belfry Therapeutics which is likely to lead to further funding applications and a patent. This has led to a CiC award application successfully reaching the panel of the latest call. |
| Start Year | 2017 |
| Description | Development of selective avb5 Integrin inhibitors as a novel treatment for Chronic Kidney disease |
| Organisation | GlaxoSmithKline (GSK) |
| Country | Global |
| Sector | Private |
| PI Contribution | Novel integrin inhibitors |
| Collaborator Contribution | Tools and assays for generating DMPK data |
| Impact | The DMPK data generated through this working collaboration between UoN, Sygnature and GSK has led to successfully reaching the panel of the latest MRC CiC call |
| Start Year | 2018 |
| Description | Development of selective avb5 Integrin inhibitors as a novel treatment for Chronic Kidney disease |
| Organisation | Sygnature Discovery Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Novel integrin inhibitors |
| Collaborator Contribution | Tools and assays for generating DMPK data |
| Impact | The DMPK data generated through this working collaboration between UoN, Sygnature and GSK has led to successfully reaching the panel of the latest MRC CiC call |
| Start Year | 2018 |
| Description | Evaluation of Toxicology of novel natural product - derived antibiotics |
| Organisation | Sygnature Discovery Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Novel compounds active against pseudomonas |
| Collaborator Contribution | Expertise in toxicology assays and insight on the requirements for commercial translation. |
| Impact | The data collected has moved the compounds identified from a previously Wellcome funded project along the translational pathway and further funding is being sought through a UK-China AMR Partnership with a third party Xenogesis |
| Start Year | 2018 |
| Description | Gershcovich: Novel formulation platforms for targeting drugs to the lymphatic system |
| Organisation | BiBerChem Research Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | A working collaboration has been created with BiBerChem and UoN. The proposed lead candidate was provided by UoN. |
| Collaborator Contribution | A range of formulations have been developed and assessed with the skills and a means of custom lipid synthesis provided by BiBerChem |
| Impact | The lead candidate has been discounted through this work and the research has taken another direction to develop formulation for efficient lymphatic transport. Studies are underway to explore this direction. |
| Start Year | 2017 |
| Description | Identification of disease modifying drugs for COPD |
| Organisation | Sygnature Discovery Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | COPD biomarkers and targets were contributed by UoN |
| Collaborator Contribution | Sygnature contributed a compound library and screening technologies. |
| Impact | AZ have approached to further this work as it is in an area of interest for them, |
| Start Year | 2017 |
| Description | John: CT/SPECT analysis for CXCR2 IPF |
| Organisation | AstraZeneca |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | A macrophage recruitment target and non-invasive imaging modality developed at UoN we contributed. |
| Collaborator Contribution | AZ have supplied expertise and a clinical asset, a novel CXCR2 agonist that is being investigated as a potential IPF therapy. Alongside determining the effect of this compound on macrophage recruitment. |
| Impact | A non-invasive imaging strategy has been further developed that will be useful to both UoN and AZ and will be explored in further collaborative projects. |
| Start Year | 2017 |
| Description | Validation of novel selective CDK9 inhibitors in an oncology model |
| Organisation | Sygnature Discovery Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | A previously funded Wellcome Trust Seeding Drug Discovery for Myotonic dystrophy resulted in the development of a number of novel and exquisitely selective CDK9 inhibitors. These where outside the scope of the Wellcome funded project however the team identified the potentially high commercial value of the molecules in the field of oncology. Through the Sygnature workshop, connections where made between UoN academics and the Sygnature team the project identified as a highly rated opportunity of interest to both teams.These novel chemistries were contributed by UoN |
| Collaborator Contribution | ADME evaluation of 10 compounds was completed by Sygnature and the same compounds where screen in cancer cell lines within UoN. |
| Impact | The collaboration with Sygnature has resulted in positive data being generated. The team continues to work together in developing a hit to lead medicinal chemistry programme to develop the novel molecules towards a new cancer treatment. A collaborative MRC DPFS application is to be drafted. |
| Start Year | 2017 |
| Title | HETEROCYCLYL SUBSTITUTED PYRROLOPYRIDINES THAT ARE INHIBITORS OF THE CDK12 KINASE |
| Description | This invention relates to compounds that are inhibitors of the CDK12 kinase. The compounds are useful in the treatment of disorders mediated by CDK12 kinase including myotonic dystrophy type 1 (DM1) and other disorders caused by the generation of RNA repeat expansion transcripts. In particular,the invention relates to compounds of the formula (I), or a pharmaceutically acceptable salts or N-oxides thereof, wherein R1a, R2, R3, R4a, R4b and R4c are as defined herein. |
| IP Reference | WO2019058132 |
| Protection | Patent application published |
| Year Protection Granted | 2019 |
| Licensed | No |
| Impact | MRC DPFS award for PI Brook and coI Hayes |